APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuromyelitis Optica Drug

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Selected research

Market Structure

Global Neuromyelitis Optica Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17401661038 January 2026198 pages

Choose your research edition.

Industry ResearchNeuromyelitis Optica Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuromyelitis Optica Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neuromyelitis Optica Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuromyelitis Optica Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuromyelitis Optica Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

Read the full market overview

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

Report Includes

This report provides an overview of the global Neuromyelitis Optica Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuromyelitis Optica Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuromyelitis Optica Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neuromyelitis Optica Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuromyelitis Optica Drug Segment by Company

Pfizer

Fresenius

Teva

Sandoz

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP

Neuromyelitis Optica Drug Segment by Type

Glucocorticoids

Immunotherapies

Others

Neuromyelitis Optica Drug Segment by Application

Acute Attack

Remission Prophylactic Treatment

Neuromyelitis Optica Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neuromyelitis Optica Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuromyelitis Optica Drug industry.

Chapter 3: Detailed analysis of Neuromyelitis Optica Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Glucocorticoids Table 3. Key Players of Immunotherapies Table 4. Key Players of Others Table 4. Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Acute Attack Table 6. Key Players of Remission Prophylactic Treatment Table 7. Global Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Neuromyelitis Optica Drug Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Neuromyelitis Optica Drug Market Share by Region (2021-2026) Table 10. Global Neuromyelitis Optica Drug Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Neuromyelitis Optica Drug Market Share by Region (2027-2032) Table 12. Neuromyelitis Optica Drug Industry Trends Table 13. Neuromyelitis Optica Drug Industry Drivers Table 14. Neuromyelitis Optica Drug Industry Opportunities and Challenges Table 15. Neuromyelitis Optica Drug Industry Restraints Table 16. Global Neuromyelitis Optica Drug Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Neuromyelitis Optica Drug Revenue Market Share by Company (2021-2026) Table 18. Global Neuromyelitis Optica Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Neuromyelitis Optica Drug Key Company Head Office and Area Served Table 20. Global Neuromyelitis Optica Drug Company, Product Type & Application Table 21. Global Neuromyelitis Optica Drug Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Neuromyelitis Optica Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Neuromyelitis Optica Drug Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Neuromyelitis Optica Drug Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021-2026) Table 28. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2027-2032) Table 29. Global Neuromyelitis Optica Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Neuromyelitis Optica Drug Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021-2026) Table 33. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2027-2032) Table 34. Pfizer Company Information Table 35. Pfizer Business Overview Table 36. Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Pfizer Neuromyelitis Optica Drug Product Portfolio Table 38. Pfizer Recent Development Table 39. Fresenius Company Information Table 40. Fresenius Business Overview Table 41. Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Fresenius Neuromyelitis Optica Drug Product Portfolio Table 43. Fresenius Recent Development Table 44. Teva Company Information Table 45. Teva Business Overview Table 46. Teva Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Teva Neuromyelitis Optica Drug Product Portfolio Table 48. Teva Recent Development Table 49. Sandoz Company Information Table 50. Sandoz Business Overview Table 51. Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Sandoz Neuromyelitis Optica Drug Product Portfolio Table 53. Sandoz Recent Development Table 54. Intas Company Information Table 55. Intas Business Overview Table 56. Intas Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Intas Neuromyelitis Optica Drug Product Portfolio Table 58. Intas Recent Development Table 59. Gyjtrs Company Information Table 60. Gyjtrs Business Overview Table 61. Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Gyjtrs Neuromyelitis Optica Drug Product Portfolio Table 63. Gyjtrs Recent Development Table 64. NANG KUANG Company Information Table 65. NANG KUANG Business Overview Table 66. NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. NANG KUANG Neuromyelitis Optica Drug Product Portfolio Table 68. NANG KUANG Recent Development Table 69. Tianjin Kingyork Company Information Table 70. Tianjin Kingyork Business Overview Table 71. Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio Table 73. Tianjin Kingyork Recent Development Table 74. Baxter Company Information Table 75. Baxter Business Overview Table 76. Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Baxter Neuromyelitis Optica Drug Product Portfolio Table 78. Baxter Recent Development Table 79. CSL Company Information Table 80. CSL Business Overview Table 81. CSL Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. CSL Neuromyelitis Optica Drug Product Portfolio Table 83. CSL Recent Development Table 84. Grifols Company Information Table 85. Grifols Business Overview Table 86. Grifols Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Grifols Neuromyelitis Optica Drug Product Portfolio Table 88. Grifols Recent Development Table 89. Octapharma Company Information Table 90. Octapharma Business Overview Table 91. Octapharma Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. Octapharma Neuromyelitis Optica Drug Product Portfolio Table 93. Octapharma Recent Development Table 94. CBOP Company Information Table 95. CBOP Business Overview Table 96. CBOP Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. CBOP Neuromyelitis Optica Drug Product Portfolio Table 98. CBOP Recent Development Table 99. North America Neuromyelitis Optica Drug Market Size by Type (2021-2026) & (US$ Million) Table 100. North America Neuromyelitis Optica Drug Market Size by Type (2027-2032) & (US$ Million) Table 101. North America Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (US$ Million) Table 102. North America Neuromyelitis Optica Drug Market Size by Application (2027-2032) & (US$ Million) Table 103. North America Neuromyelitis Optica Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America Neuromyelitis Optica Drug Market Size by Country (2021-2026) Table 105. North America Neuromyelitis Optica Drug Market Size by Country (2027-2032) Table 106. Europe Neuromyelitis Optica Drug Market Size by Type (2021-2026) & (US$ Million) Table 107. Europe Neuromyelitis Optica Drug Market Size by Type (2027-2032) & (US$ Million) Table 108. Europe Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (US$ Million) Table 109. Europe Neuromyelitis Optica Drug Market Size by Application (2027-2032) & (US$ Million) Table 110. Europe Neuromyelitis Optica Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Europe Neuromyelitis Optica Drug Market Size by Country (2021-2026) Table 112. Europe Neuromyelitis Optica Drug Market Size by Country (2027-2032) Table 113. China Neuromyelitis Optica Drug Market Size by Type (2021-2026) & (US$ Million) Table 114. China Neuromyelitis Optica Drug Market Size by Type (2027-2032) & (US$ Million) Table 115. China Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (US$ Million) Table 116. China Neuromyelitis Optica Drug Market Size by Application (2027-2032) & (US$ Million) Table 117. Asia Neuromyelitis Optica Drug Market Size by Type (2021-2026) & (US$ Million) Table 118. Asia Neuromyelitis Optica Drug Market Size by Type (2027-2032) & (US$ Million) Table 119. Asia Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (US$ Million) Table 120. Asia Neuromyelitis Optica Drug Market Size by Application (2027-2032) & (US$ Million) Table 121. Asia Neuromyelitis Optica Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Asia Neuromyelitis Optica Drug Market Size by Country (2021-2026) Table 123. Asia Neuromyelitis Optica Drug Market Size by Country (2027-2032) Table 124. South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2021-2026) & (US$ Million) Table 125. South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2027-2032) & (US$ Million) Table 126. South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2021-2026) & (US$ Million) Table 127. South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2027-2032) & (US$ Million) Table 128. South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021-2026) Table 130. South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2027-2032) Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Neuromyelitis Optica Drug Product Image Figure 2. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neuromyelitis Optica Drug Market Share by Type: 2025 VS 2032 Figure 4. Glucocorticoids Image Figure 5. Immunotherapies Image Figure 6. Others Image Figure 7. Global Neuromyelitis Optica Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Neuromyelitis Optica Drug Market Share by Application: 2025 VS 2032 Figure 9. Acute Attack Image Figure 10. Remission Prophylactic Treatment Image Figure 11. Global Neuromyelitis Optica Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 13. Global Neuromyelitis Optica Drug Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Neuromyelitis Optica Drug Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Neuromyelitis Optica Drug Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Neuromyelitis Optica Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Neuromyelitis Optica Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021-2032) Figure 22. North America Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 23. North America Neuromyelitis Optica Drug Market Share by Type (2021-2032) Figure 24. North America Neuromyelitis Optica Drug Market Share by Application (2021-2032) Figure 25. North America Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 26. United States Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 27. Canada Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 29. Europe Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 30. Europe Neuromyelitis Optica Drug Market Share by Type (2021-2032) Figure 31. Europe Neuromyelitis Optica Drug Market Share by Application (2021-2032) Figure 32. Europe Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 33. Germany Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 34. France Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 36. Italy Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 37. Russia Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 39. China Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 40. China Neuromyelitis Optica Drug Market Share by Type (2021-2032) Figure 41. China Neuromyelitis Optica Drug Market Share by Application (2021-2032) Figure 42. Asia Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 43. Asia Neuromyelitis Optica Drug Market Share by Type (2021-2032) Figure 44. Asia Neuromyelitis Optica Drug Market Share by Application (2021-2032) Figure 45. Asia Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 46. Japan Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 50. India Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 51. Australia Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Neuromyelitis Optica Drug Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Neuromyelitis Optica Drug Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Neuromyelitis Optica Drug Market Share by Country (2021-2032) Figure 56. Brazil Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 61. UAE Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 63. Chile Neuromyelitis Optica Drug Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Glucocorticoids
  • Immunotherapies
  • Others
Applications
  • Acute Attack
  • Remission Prophylactic Treatment
Companies covered
  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Glucocorticoids
  5. 1.2.3 Immunotherapies
  6. 1.2.4 Others
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Acute Attack
  10. 1.3.3 Remission Prophylactic Treatment
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Neuromyelitis Optica Drug Growth Trends by Region
  13. 1.5.1 Global Neuromyelitis Optica Drug Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Neuromyelitis Optica Drug Market Size by Region (2021-2026)
  15. 1.5.3 Neuromyelitis Optica Drug Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Neuromyelitis Optica Drug Market Dynamics
  1. 2.1 Neuromyelitis Optica Drug Industry Trends
  2. 2.2 Neuromyelitis Optica Drug Industry Drivers
  3. 2.3 Neuromyelitis Optica Drug Industry Opportunities and Challenges
  4. 2.4 Neuromyelitis Optica Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neuromyelitis Optica Drug Revenue by Company (2021-2026)
  2. 3.2 Global Neuromyelitis Optica Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neuromyelitis Optica Drug Key Company Head office and Area Served
  4. 3.4 Global Neuromyelitis Optica Drug Company, Product Type & Application
  5. 3.5 Global Neuromyelitis Optica Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neuromyelitis Optica Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neuromyelitis Optica Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neuromyelitis Optica Drug Tier 1, Tier 2, and Tier 3
4 Neuromyelitis Optica Drug Market by Type
  1. 4.1 Global Neuromyelitis Optica Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neuromyelitis Optica Drug Market Size by Type (2021-2032)
  3. 4.3 Global Neuromyelitis Optica Drug Market Size Share by Type (2021-2032)
5 Neuromyelitis Optica Drug Market by Application
  1. 5.1 Global Neuromyelitis Optica Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuromyelitis Optica Drug Market Size by Application (2021-2032)
  3. 5.3 Global Neuromyelitis Optica Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Pfizer Neuromyelitis Optica Drug Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 Fresenius
  8. 6.2.1 Fresenius Company Information
  9. 6.2.2 Fresenius Business Overview
  10. 6.2.3 Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Fresenius Neuromyelitis Optica Drug Product Portfolio
  12. 6.2.5 Fresenius Recent Developments
  13. 6.3 Teva
  14. 6.3.1 Teva Company Information
  15. 6.3.2 Teva Business Overview
  16. 6.3.3 Teva Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Teva Neuromyelitis Optica Drug Product Portfolio
  18. 6.3.5 Teva Recent Developments
  19. 6.4 Sandoz
  20. 6.4.1 Sandoz Company Information
  21. 6.4.2 Sandoz Business Overview
  22. 6.4.3 Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Sandoz Neuromyelitis Optica Drug Product Portfolio
  24. 6.4.5 Sandoz Recent Developments
  25. 6.5 Intas
  26. 6.5.1 Intas Company Information
  27. 6.5.2 Intas Business Overview
  28. 6.5.3 Intas Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Intas Neuromyelitis Optica Drug Product Portfolio
  30. 6.5.5 Intas Recent Developments
  31. 6.6 Gyjtrs
  32. 6.6.1 Gyjtrs Company Information
  33. 6.6.2 Gyjtrs Business Overview
  34. 6.6.3 Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Gyjtrs Neuromyelitis Optica Drug Product Portfolio
  36. 6.6.5 Gyjtrs Recent Developments
  37. 6.7 NANG KUANG
  38. 6.7.1 NANG KUANG Company Information
  39. 6.7.2 NANG KUANG Business Overview
  40. 6.7.3 NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 NANG KUANG Neuromyelitis Optica Drug Product Portfolio
  42. 6.7.5 NANG KUANG Recent Developments
  43. 6.8 Tianjin Kingyork
  44. 6.8.1 Tianjin Kingyork Company Information
  45. 6.8.2 Tianjin Kingyork Business Overview
  46. 6.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio
  48. 6.8.5 Tianjin Kingyork Recent Developments
  49. 6.9 Baxter
  50. 6.9.1 Baxter Company Information
  51. 6.9.2 Baxter Business Overview
  52. 6.9.3 Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Baxter Neuromyelitis Optica Drug Product Portfolio
  54. 6.9.5 Baxter Recent Developments
  55. 6.10 CSL
  56. 6.10.1 CSL Company Information
  57. 6.10.2 CSL Business Overview
  58. 6.10.3 CSL Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 CSL Neuromyelitis Optica Drug Product Portfolio
  60. 6.10.5 CSL Recent Developments
  61. 6.11 Grifols
  62. 6.11.1 Grifols Company Information
  63. 6.11.2 Grifols Business Overview
  64. 6.11.3 Grifols Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Grifols Neuromyelitis Optica Drug Product Portfolio
  66. 6.11.5 Grifols Recent Developments
  67. 6.12 Octapharma
  68. 6.12.1 Octapharma Company Information
  69. 6.12.2 Octapharma Business Overview
  70. 6.12.3 Octapharma Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Octapharma Neuromyelitis Optica Drug Product Portfolio
  72. 6.12.5 Octapharma Recent Developments
  73. 6.13 CBOP
  74. 6.13.1 CBOP Company Information
  75. 6.13.2 CBOP Business Overview
  76. 6.13.3 CBOP Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 CBOP Neuromyelitis Optica Drug Product Portfolio
  78. 6.13.5 CBOP Recent Developments
7 North America
  1. 7.1 North America Neuromyelitis Optica Drug Market Size (2021-2032)
  2. 7.2 North America Neuromyelitis Optica Drug Market Size by Type
  3. 7.2.1 North America Neuromyelitis Optica Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Neuromyelitis Optica Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Neuromyelitis Optica Drug Market Share by Type (2021-2032)
  6. 7.3 North America Neuromyelitis Optica Drug Market Size by Application
  7. 7.3.1 North America Neuromyelitis Optica Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Neuromyelitis Optica Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Neuromyelitis Optica Drug Market Share by Application (2021-2032)
  10. 7.4 North America Neuromyelitis Optica Drug Market Size by Country
  11. 7.4.1 North America Neuromyelitis Optica Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neuromyelitis Optica Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Neuromyelitis Optica Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Neuromyelitis Optica Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neuromyelitis Optica Drug Market Size (2021-2032)
  2. 8.2 Europe Neuromyelitis Optica Drug Market Size by Type
  3. 8.2.1 Europe Neuromyelitis Optica Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neuromyelitis Optica Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neuromyelitis Optica Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Neuromyelitis Optica Drug Market Size by Application
  7. 8.3.1 Europe Neuromyelitis Optica Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neuromyelitis Optica Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neuromyelitis Optica Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Neuromyelitis Optica Drug Market Size by Country
  11. 8.4.1 Europe Neuromyelitis Optica Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neuromyelitis Optica Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neuromyelitis Optica Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neuromyelitis Optica Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neuromyelitis Optica Drug Market Size (2021-2032)
  2. 9.2 China Neuromyelitis Optica Drug Market Size by Type
  3. 9.2.1 China Neuromyelitis Optica Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Neuromyelitis Optica Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Neuromyelitis Optica Drug Market Share by Type (2021-2032)
  6. 9.3 China Neuromyelitis Optica Drug Market Size by Application
  7. 9.3.1 China Neuromyelitis Optica Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Neuromyelitis Optica Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Neuromyelitis Optica Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neuromyelitis Optica Drug Market Size (2021-2032)
  2. 10.2 Asia Neuromyelitis Optica Drug Market Size by Type
  3. 10.2.1 Asia Neuromyelitis Optica Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neuromyelitis Optica Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neuromyelitis Optica Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Neuromyelitis Optica Drug Market Size by Application
  7. 10.3.1 Asia Neuromyelitis Optica Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neuromyelitis Optica Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neuromyelitis Optica Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Neuromyelitis Optica Drug Market Size by Country
  11. 10.4.1 Asia Neuromyelitis Optica Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neuromyelitis Optica Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neuromyelitis Optica Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neuromyelitis Optica Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neuromyelitis Optica Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neuromyelitis Optica Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neuromyelitis Optica Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst